Cancer treatment by photodynamic therapy combined with NK cell line based adoptive immunotherapy

Proceedings of SPIE - The International Society for Optical Engineering

Volumn 3254, Issue , 1998, Pages 4-11

  Korbelik, Mladen ^a   Sun, Jinghai ^a  

^a BRITISH COLUMBIA CANCER AGENCY   (Canada)

Author keywords

Adoptive immunotherapy; NK cell line; Photodynamic therapy; Tumor draining lymph nodes

Indexed keywords

ANTIGEN-ANTIBODY REACTIONS; FLAMMABILITY; IMMUNOLOGY; ONCOGENIC VIRUSES; ONCOLOGY;

ADOPTIVE IMMUNOTHERAPY;

PHOTODYNAMIC THERAPY;

EID: 0032223944     PISSN: 0277786X     EISSN: None     Source Type: Conference Proceeding    
DOI: 10.1117/12.308148     Document Type: Conference Paper

References (39)

1. Clinical and preclinical photodynamic therapy
2. Induction of tumor immunity by photodynamic therapy
3. Photochemotherapy of cancer: Basic concepts and clinical applications
4. Cellular targets and molecular responses associated with photodynamic therapy
5. Induction of glucose regulatory proteins in tumor cells after treatment with benzophenothiazine analogue
6. Tumor antigens recognized by T lymphocytes
7. Photophysical and photobiological processes in the photodynamic therapy
8. Vascular effects of photodynamic therapy
9. Induction of immune cell infiltration into murine SCCVII tumour by photofrin-based photodynamic therapy
10. Altered expression of interleukin 6 and interleukin 10 as a result of photodynamic therapy in vivo
11. Photosensitizer distribution and photosensitized damage of tumor tissues
12. Adhesion receptors of the immune system
13. Pivotal role of the B7:CD28 pathway in transplantation tolerance and tumor immunity
14. The immunotherapy and gene therapy of cancer
15. Treatment of patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and interleukin 2
16. Specific adoptive immunotherapy mediated by tumor-draining lymph node cells sequentially activated with anti-CD3 and IL-2
17. Antibodies to Tp67 and Tp44 augment and sustain proliferative responses of activated T cells
18. Treatment of subcutaneous tumor with adoptively transferred T cells
19. Adoptive immunotherapy of malignant glioma using tumor-sensitized T lymphocytes
20. In vivo antitumor activity of tumor-infiltrating lymphocytes expanded in recombinant interleukin-2
21. Generation of T-cells reactive to the poorly immunogenic B16-BL6 melanoma with efficacy in the treatment of spontaneous metastases
22. Accessory cell independent proliferation of human T4 cells stimulated by immobilized monoclonal antibodies to CD3
23. In vivo antitumor efficacy of tumor-draining lymph node cells activated with nonspecific T-cell reagents
24. Cellular interactions in effector cell generation and tumor regression mediated by anti-CD3/interleukin 2-activated tumor-draining lymph node cells
25. Phenotype analyses and cellular mechanism of the pre-effector T-lymphocyte response to a progressive syngeneic murine sarcoma
26. Biology and relevance of bureau natural killer cells
27. Interleukin 7 enhances cytolytic T lymphocyte generation and induces lymphokine-activated killer cells from human peripheral blood
28. Response of human natural killer (NK) cells to NK cell stimulatory factor (NKSF): Cytolytic activity and proliferation of NK cells axe differentially regulated by NKSF
29. Dissection of the lymphokine activated killer phenomenon: Relative contribution of peripheral blood natural kiler cell and T lymphocytes to cytolysis
30. Human natural killer cells in health and disease
31. Adoptive immunotherapy of established pulmonary metastases with LAK cells and recombinant interleukin-2
32. Treatment of cancer patients with ex vivo anti-CD3-activated killer cells and interleukin-2
33. TCGF (IL2)-receptor inducing factor(s). I. Regulation of IL2 receptor on a natural killer-like cell line (YT cells)
34. Characterization of a human cell line (NK-92) with phenotypical and functional characteristics of activated natural killer cells
35. A cytotoxic NK-cell line (NK-92) for ex vivo purging of leukemia from blood
36. "dim"+ lymphokine-activated killer cells
37. Morphological studies of effector cell-microvessel interactions in adoptive immunotherapy in tumor-bearing animals
38. Transfection of transforming growth factor-β producing tumor EMT6 with interleukin-2 elicits tumor rejection and tumor reactive cytotoxic T-lymphocytes
39. The role of host lymphoid populations in the response of mouse EMT6 tumor to photodynamic therapy